Integration of ERG gene mapping and gene‐expression profiling identifies distinct categories of human prostate cancer
暂无分享,去创建一个
Daniel Brewer | Rosalind Eeles | Sandra Edwards | Anders Bjartell | Gerhardt Attard | Cyril Fisher | Jeremy Clark | R. Eeles | Z. Kote-Jarai | C. Woodhouse | A. Thompson | T. Christmas | C. Ogden | C. Cooper | S. Jhavar | C. Fisher | A. Norman | R. Playford | U. Stenman | G. Kovacs | D. Brewer | A. Bjartell | Jeremy Clark | P. Flohr | S. Edwards | G. Attard | C. Corbishley | C. Jameson | Penny Flohr | Colin S Cooper | Zsofia Kote-Jarai | Gyula Kovacs | Sameer Jhavar | Charles Jameson | Alan Thompson | Raymond J Playford | Cathy Corbishley | Christopher Ogden | Christopher Woodhouse | Timothy Christmas | Matthew Parker | Christopher Shepherd | Ulf-Hakan Stenman | Tania Marchbank | Andy Norman | Johann De-Bono | T. Marchbank | J. de-Bono | C. Shepherd | M. Parker | Christopher J. Shepherd | Matthew Parker
[1] L. Pardo,et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. , 2007, Cancer research.
[2] G. Jenster,et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.
[3] D. Bostwick,et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.
[4] R. Eeles,et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.
[5] P. Singh,et al. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. , 2008, European journal of cancer.
[6] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] L. Liotta,et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. , 1998, Journal of the National Cancer Institute.
[8] Rosalind Eeles,et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome , 2004, Oncogene.
[9] Y Pawitan,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[10] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[11] Gordon K. Smyth,et al. limma: Linear Models for Microarray Data , 2005 .
[12] U. Stenman,et al. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. , 2007, European urology.
[13] M. Becich,et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Varambally,et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. , 2008, Cancer research.
[15] M. Marberger,et al. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. , 1999, Techniques in urology.
[16] Debashis Ghosh,et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.
[17] C. Roehrborn,et al. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. , 1999, The Journal of urology.
[18] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[19] T. Golub,et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.
[20] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[21] J. Veltman,et al. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines , 2004, Genes, chromosomes & cancer.
[22] D. Bostwick,et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia , 1998, Cancer.
[23] John T. Wei,et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.
[24] S. Dhanasekaran,et al. Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.
[25] S. Dhanasekaran,et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.
[26] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[27] S. Nordling,et al. High tissue expression of tumour‐associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer , 2005, Histopathology.
[28] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[29] C. Cooper,et al. A Gene Expression Signature Associated with Metastatic Outcome in Human Leiomyosarcomas , 2004, Cancer Research.
[30] Colin Campbell,et al. The Latent Process Decomposition of cDNA Microarray Data Sets , 2005, TCBB.
[31] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] A. Evans,et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.
[33] U. Stenman,et al. Biochemistry and Clinical Role of Trypsinogens and Pancreatic Secretory Trypsin Inhibitor , 2006, Critical reviews in clinical laboratory sciences.
[34] D. Johnston,et al. Detailed mapping of prostate carcinoma foci , 2000, Cancer.
[35] G. Miller,et al. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. , 1994, The Journal of urology.
[36] Alberto Riva,et al. Defining aggressive prostate cancer using a 12-gene model. , 2006, Neoplasia.
[37] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[38] M. Miyazaki,et al. Relationship Between Pancreatic Secretory Trypsin Inhibitor and Early Recurrence of Intrahepatic Cholangiocarcinoma Following Surgical Resection , 2006, The American Journal of Gastroenterology.
[39] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.
[40] P. Roy-Burman,et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. , 1995, The American journal of pathology.
[41] Z. Szallasi,et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.
[42] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[43] E. Lander,et al. A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.
[44] W. Gerald,et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy , 2005, Cancer.
[45] C Cummings,et al. Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique , 2005, Journal of Clinical Pathology.
[46] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[47] Lei Wang,et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. , 2006, Neoplasia.
[48] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.
[49] CampbellColin,et al. The Latent Process Decomposition of cDNA Microarray Data Sets , 2005 .
[50] T. Stamey,et al. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors , 1992, Cancer.
[51] J. Cuzick,et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.
[52] L. Klotz,et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.
[53] Arul M Chinnaiyan,et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.
[54] C. Cooper,et al. Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer , 2007, Nature Clinical Practice Urology.
[55] Lang Li,et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate , 2004, Cancer.
[56] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[57] O. Kallioniemi,et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.
[58] G. Glinsky,et al. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.
[59] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[60] R. Eeles,et al. Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. , 2008, The Journal of molecular diagnostics : JMD.
[61] T. Wheeler,et al. Heterogeneity of prostate cancer in radical prostatectomy specimens. , 1994, Urology.
[62] D. Bostwick,et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.
[63] N. Konishi,et al. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. , 1995, The American journal of pathology.
[64] M. Rubin,et al. TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.
[65] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.